Acalabrutinib
Acalabrutinib Brand Name – CALQUENCE What is Acalabrutinib Acalabrutinib is a Bruton tyrosine kinase (BTK) inhibitor approved for the treatment of mantle cell lymphoma in adult patients who have received at least 1 prior therapy and as a single-agent or in combination with obinutuzumab in adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma. …